Insiders who reported open-market trades in the last 12 months at the companies M33 Growth I L.P. files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Jorey Chernett - $2.69M in STLN purchases and sales in the last 12 months
Brad Hively - $2.00M in STLN purchases and sales in the last 12 months
Mohit Kaushal - $335K in STLN purchases and sales in the last 12 months
Yale Podnos - $276K in STLN purchases and sales in the last 12 months
Mark L. Pacala - $200K in STLN purchases and sales in the last 12 months
Robert Ross Carter - $879 in STLN purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
M33 Growth I L.P. is an investment firm, tracked as Director of Starling Oncology, Inc. (STLN). InsiderAlpha holds 2 primary Form 4 filings for it, the earliest from 2025, updated as new SEC EDGAR filings are processed.
When did M33 Growth I L.P. last file a Form 4?
The most recent primary Form 4 on record is dated 20 November 2025, one of 2 filings going back to 2025.
Has M33 Growth I L.P. been buying or selling stock?
Recorded transactions: 0 open-market purchases and 2 open-market sales ($20.70M) across all tracked filings.
M33 Growth I L.P. is Director of Starling Oncology, Inc. (STLN). 2 SEC Form 4 filings on record, most recently on 20 November 2025. Most recent open-market trade: sold $2.11M of STLN on 4 September 2025. Lifetime open-market sales: $20.70M.
Recent transactions
5
The latest 5 SEC Form 4 transactions reported by M33 Growth I L.P..
InsiderAlpha's records for M33 Growth I L.P. go back to 2025: 2 primary Form 4 filings, an average of 1.0 per year. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
